✦ LIBER ✦

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

✍ Scribed by Joseph Chao; Timothy W. Synold; Robert J. Morgan; Charles Kunos; Jeff Longmate; Heinz-Josef Lenz; Dean Lim; Stephen Shibata; Vincent Chung; Ronald G. Stoller; Chandra P. Belani; David R. Gandara; Mark McNamara; Barbara J. Gitlitz; Derick H. Lau; Suresh S. Ramalingam; Angela Davies; Igor Espinoza-Delgado; Edward M. Newman; Yun Yen

Publisher: Springer
Year: 2011
Tongue: English
Weight: 259 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-011-1779-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of GTI-2040, oxaliplatin,

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

✍ Stephen I. Shibata; James H. Doroshow; Paul Frankel; Timothy W. Synold; Yun Yen; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 310 KB

A Phase I study of the novel ribonucleot

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

✍ Judith E. Karp; Francis J. Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 117 KB